SG Veredus & ST Microelectronics' 2 hour swine flu test kit

• lionnoisy

  14 Jul 09, 10:35

  “VereFlu”---jointly developed by

  Singapore home grown Veredus & global company ST Microelectronics' can test  swine flu in 2 hours.

  @@@@@@@@@@@@@@@

  Veredus Laboratories.,after providing bird flu test kits to US Navy 7 th Fleet few years ago,now roll out swine flu quick test kit with ST M!!

  Sg already helped to protect US Navy 7th Fleet in quick bird flu test kit

  

  US 7 th Fleet flag ship Blue Ridge

  It takes 2 hours for this SG developed swine flu test kit to test!!

  In this swine flu crisis,We have to thank we have a very strong R & D teams

  in public as well as private sectors.Also,it is useless unless we have a strong manufacturing sectors to produce in mass scale and affordable cost.

  SG bio-medical industries is well known

  by insiders.Read again to appreciate the speed of Singapore,though a little boring without gun shooting in neighbourhood!!

  2.Speed,price and capacity to produce in mass production

  A.there are two speeds we need to concern.First ,the kit must give a answer fast.

  Secondly,the test kit are needed very urgently.Therefore speed to mass production is first key.

  B.If the test kit is priced beyond affordability in mass scale,it is not marketable.

  Governement around the world need it in big quantity.Therefore,the price cant be too high.

  C.It must be able to be produced in mass scale.

  @@@@@@@@@

  Many countries can develop test kit,but cannot produce results fast enough,produce in mass scale fast enough and affordable price.We can!!
  

  U may probably read there are many other countries who claim they have produced the first swine test kit.Unfortunalely,they lack one or more of the factors mentioned above.Therefore,u have not seen the products in the market in mass scale,yet.

  Sometimes.political will need to push up the intergrations of R & D ,share of knowledges and manufacturing.We dunt know how SG gavaman involved in this kit.

  Nvm,u can read fr zaobao news below that SG MOH alreday made the order of this new test kit in late April .The test kit had been handed over to MOH before the confiramtion of first swine flu case.

  Price is between US$120 to 180 a piece.

  陈淑彬Rose Mary �露，早在4月28日，也就是我国将�感警戒从绿色调高到黄色当天，�生部已�订购测试�感病毒的晶片。公�两天内将H1N1�感病毒设置在晶片内，并在两个星期内，也就是我国出现首个确诊病例�，就把晶片交给公共�生实验室。�个VereFlu

  晶片的售价介于120至180美元之间

  Many countries can develop test kit,but cannot produce results fast enough,produce in mass scale fast enough and affordable price.

  platform---“VereFlu”:

  The platform can be rapidly adapted
  to mutations of pathogens. Example:
  April 23: CDC confirms swine flu virus
  April 26: Mutated sequence received
  by our team
  April 29: Press release confirming that
  VereFlu can detect mutation
  May 10: New chips ready to validate
  modified test on patient samples

  pages 19 and 20 from

  [PDF] Microsoft PowerPoint - 5-Multimedia Convergency & ACCI Overview ... ... Innovative full kits Optimized ASIC & ASSP Solutions ... Example: April 23: CDC confirms
  swine flu virus ... modified test on patient samples Page 21. ...
  www.st.com/stonline/press/news/year2009/5_mult_conv_acci_lambinet.pdf - 2009-05-25

  and

  Veredus Laboratories.

  references

   

  STMicroelectronics and Veredus Laboratories Launch Market's First ...

   - [ 翻译此页 ]24 Mar 2008 ... About Veredus Laboratories Pte Ltd Founded in 2003, Veredus Laboratories Pte Ltd is ... Hire a stripper · U.S. swine flu case numbers rise, ...
  www.reuters.com/.../idUS47761+24-Mar-2008+PRN20080324

  aaaa

  jjjj

  jjjj

  We alredat Protect US mighty 7 th Fleet few years ago!!

  our Bio Chem warfare is not so weak.

  VX & Sarin gas---Spore ability in Bio Chem protection

  @@@@@@@@@@@@

  On-board Avian Flu Testing Labs on US Navy Ships ( A Singapore ...

   - [ 翻译此页 ]Veredus founded three years ago also makes malaria and dengue te...The Japan-

  based Seventh Fleet has 50 vessels and 20000 active per.
  www.bio-medicine.org/.../On-board-Avian-Flu-Testing-Labs-on-US-Navy-Ships-12833-1/ -

  
  

  PRESS RELEASE Veredus Laboratories and the United States Navy's ...

  @@@@@@@@@@2

  本地公�和�法�导体��生产 晶片测�感　�需两�时

  （2009-07-07）

  陈颖佳　报�

  本地公�Veredus实验室和�法�导体(ST Microelectronics)��生产的VereFlu晶片，能在两�时内检验病人感染哪类�感病毒。

  我国最近�生甲型H1N1�感疫情时，�生部公共�生实验室就使用这款晶片，对�感病患进行检测。

  Veredus实验室总�陈淑彬�士接�本报访问时说，公�预��感病毒将造�下一场大�行病，并在两年�开�测试多���类型�感病毒的晶片。

  陈淑彬�露，早在4月28日，也就是我国将�感警戒从绿色调高到黄色当天，�生部已�订购测试�感病毒的晶片。公�两天内将H1N1�感病毒设置在晶片内，并在两个星期内，也就是我国出现首个确诊病例�，就把晶片交给公共�生实验室。

  她说：“H5N1禽æµ�感首次出现时，实验室需è¦�七到å��天æ‰�能确诊。目å‰�，我们的技术能在四到六个å°�时内辨别出å��多ç§�æµ�感，大大å‡�少化验时间。”

  陈淑彬指出，VereFlu晶片�带轻便，而且使用容易，�在医院�诊所�机场��房�家中�农场等使用，而���于实验室。

  她表示，公�正在探讨如何进一步改良晶片，使家庭医生也能用它测试病人感染哪些类型的�感。

  �生部最近调整对抗甲�的策略，从抑制疾病的蔓延，转�缓和疾病的冲击。

  �生部密切留�H1N1病毒是���，以�计算普�率，因此能化验��类型�感病毒的晶片能派上用场。

  公共å�«ç”Ÿå®žéªŒå®¤ä¸»ç®¡æž—择彬副教授通过Vereduså�‘表的文告说：“这次的H1N1æµ�感疫情显示监测æµ�感活动至关é‡�è¦�。éš�ç�€æ›´å¤šæœ¬åœ°å®žéªŒå®¤æŠ•å…¥ç›‘测æµ�感病毒的任务，我们很高兴本地ä¼�业有能力æ��供监测æµ�感病毒的新技术。”
  陈淑彬说，公�接下�将加强晶片的检测能力，若�感病毒产生抗�性��早�现。
  �个VereFlu晶片的售价介于120至180美元之间，而一些亚洲和中东国家已�试点使用VereFlu晶片。
  一患者有并�症�加护病房
    ã€€ä¸€å��63å²�ç”·å­�å‰�天ç»�诊断å�Žï¼Œç¡®å®šä¸ºç”²åž‹H1N1æµ�感患者，由于å�Œæ—¶è¿˜æœ‰å¥½å‡ ç§�疾病，他昨早被é€�入陈笃生医院加护病房，接å�—密切观察，病况令人关注。
  �生部昨晚�出文告说，本地昨天出现56起新确诊甲�病例，上述男�是其中一�病患。本地总病例已达1111起。
  这�患者是在出现感冒症状的三天�，也就是本月5日�往陈笃生医院的急诊部门求医。由于病患出现其他并�症包括肺炎和心�病，医院立�安排他留医和接 �隔离治疗。当晚，他被确诊为甲�患者，并开始�用达�（Tamiflu）。因病患已患有共存疾病（co-morbidities），如冠状动脉疾病 (coronary heart disease)�高血压�高血脂等，医院昨早将他转入加护病房。医院目�正密切观察他的病情进展。
  亚���尼团一男�确诊
  �外，亚洲�年�动会�尼代表团的一�40�男�也在�天确诊为甲�患者，目�情况稳定。�生部已�求与他接触频�的两人在家隔离，两人目�情况良 好。根��生部的文告，这��尼甲�患者在本月2日开始出现感冒症状�，接��尼队医生的治疗，并在三天�到亚��医疗中心就诊。
  文告说，昨天的56起新确诊甲�病例中，多数病患的病情轻微。�生部的抽样检测也�现，本地有�感症状的病人中有13%是甲�患者，这个比例在6月 26日时是5%。以其他国家的观察�看，当甲�病毒的社区感染扩大�，甲�患者在总�感患者中所�的比例也会增高，并���代其他�感病毒。�过目�甲� 所造�的病情�然轻微，�有带有潜�病情的高�病患�能会出现并�症，甚至造�死亡。
  公众�拨打热线1800-3339999，或上�生部网站www.moh.gov.sg查询�感诊所的详情与�生部的最新消�。　
  

  《��早报》

  http://www.laoyaoba.com/forums/viewthread.php?tid=8564

  http://www.zaobao.com.sg/sp/sp090707_011.shtml

   

   
• SingaporeTyrannosaur

  15 Jul 09, 23:09

  Singapore loses race to develop the first DNA test kit for H1N1

  First DNA Test Kit For H1N1 Influenza A (Swine Flu) Arrives

  May 10, 2009 - 2:36pm

  <!-- start main content --><!-- Wack, man. -->

  PrimerDesign Ltd, a UK firm founded by University of Southampton scientists, has won the race to produce the first DNA test kit for the Mexican swine flu.

  The first shipment of rapid-results tests has been sent today directly to Mexico as well as many other territories to help authorities monitor the increasing number of suspected cases.

  Project coordinator Dr Rob Powell said: "This past Sunday at midnight was a very special moment for us. We were able to show conclusively that the test works."

  The rapid test has results in only two hours compared to current diagnostic tests which take two days.

  "Monitoring the spread of the virus is now the key weapon against a possible pandemic. These tests will contribute to the global effort to halt the disease," said Dr Jim Wicks from PrimerDesign.

  The company is part of the University's SETsquared Business Incubation programme.

  The PrimerDesign swine flu real-time PCR kit is sold primarily for research use but could be used to diagnose the disease in laboratories globally.

•  

  Other nations beat Singapore to development on rapid H1N1 test kit

  Use of Rapid Influenza Diagnostic Tests for Patients with Influenza-like Illness during the Novel H1N1 Influenza Virus (Swine Flu) Outbreak

  Information for Health Care Professionals

  May 2, 2009 10:00 PM ET

  Background

  Rapid influenza diagnostic tests can help in the diagnosis and management of patients who present with signs and symptoms compatible with influenza. Such tests detect seasonal influenza A and B viral nucleoprotein antigens in respiratory specimens. The currently circulating novel H1N1 influenza virus (also referred to as swine flu) is an influenza A virus. Data are not yet available to inform recommendations on the use of rapid influenza diagnostic tests in patients with novel H1N1 virus infection. It is reasonable to assume that rapid diagnostic tests that detect influenza A viral nucleoprotein antigen can detect novel H1N1 flu infection in respiratory specimens as these nucleoprotein antigens are highly conserved across influenza A viruses. However, the sensitivity and specificity of the different rapid tests is not yet known for this novel virus. CDC has received anecdotal reports of false positive and false negative results. Clinicians may consider using rapid diagnostic tests as part of their evaluation of patients with signs and symptoms compatible with influenza, but results should be interpreted with caution. Confirmation of novel H1N1 flu infection can only be made by reverse-transcription polymerase chain reaction (RT-PCR) or viral culture.

  Reliability and Interpretation of Rapid Influenza Test Results

  The reliability of rapid influenza diagnostic tests depends largely on the conditions under which they are used, and are entirely based on the experience with seasonal influenza.

  • For detection of seasonal influenza virus infection, sensitivities of rapid diagnostic tests are approximately 50-70% when compared with viral culture or RT-PCR, and specificities of rapid diagnostic tests for influenza are approximately 90-95%. Sensitivity and specificity of these tests for detection of the novel H1N1 flu virus are unknown.
  • False-positive (and true-negative) results are more likely to occur when influenza is uncommon in the community, which is generally at the beginning and end of an outbreak.
  • False-negative (and true-positive) results are more likely to occur when influenza is common in the community, which is typically at the height of an outbreak.
  • Test sensitivity may vary depending on when in the course of illness the specimen is collected. Respiratory specimens for testing should be collected in the first 4-5 days of illness when viral shedding is greatest.

  Given these limitations, the decision of whether or not to test patients with rapid influenza diagnostic tests should be based upon the patient’s presenting symptoms, whether or not cases of novel H1N1 have been confirmed in the area, and/or the patient’s risk for severe disease or other complications.

  • How to interpret a positive test result:
    
    

    A patient testing positive for influenza B by rapid diagnostic test likely has been infected with seasonal influenza B virus that is continuing to circulate or is a false-positive result. Such a patient is unlikely to have novel H1N1 virus infection.

    
    There are several possibilities when a patient tests positive for influenza A by rapid antigen test:

    • The patient might have novel H1N1 virus infection
    • The patient might have seasonal influenza A virus infection or
    • The patient might have a false positive test result.
    
    
  • Information provided by states and local health authorities should be consulted to determine whether public health authorities are advising that patients who test positive on a rapid influenza antigen test need additional testing. In areas with many new confirmed cases of novel H1N1 flu infection and where community spread of H1N1 is occurring, patients who test positive on a rapid influenza diagnostic test can be treated empirically with antiviral medications if clinically indicated (see Interim Guidance on Antiviral Recommendations for Patients with Novel Influenza A (H1N1) Virus Infection and Their Close Contacts ) without further testing.. In areas with no or few confirmed cases of novel H1N1 flu, a nasopharyngeal swab/aspirate or nasal aspirate should be collected and sent to the state public health laboratory for RT-PCR to determine if the patient has H1N1 infection, seasonal influenza A virus infection, or a false-positive test result. See Interim guidelines for specimen collection and Interim biosafety guidelines for laboratory workers.
    
  • How to interpret a negative result:
    
    Novel H1N1 flu virus infection cannot be excluded when a patient tests negative for influenza A by rapid antigen test. If the patient has an epidemiologic link to a confirmed case (i.e. had close contact with a confirmed case), or has either traveled to or resides in a community where there are one or more confirmed novel H1N1 cases, further testing and treatment should be based upon clinical suspicion, severity of illness, and risk for complications. If there is no epidemiologic link and the patient has mild illness, further testing and treatment are not recommended.